Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

202130 citationsJournal Articlegold Open Access

Authors

ClinicalTrials.gov, NCT03789292 . Registered 28 December 2018-retrospectively registered.

Good health and well-being

Published in: Arthritis Research & Therapy

Volume 23, Issue 1, pp. 51-51

Field-Weighted Citation Impact: 2.13